EATG » Hepatitis

Hepatitis

NHS England strikes world leading deal to help eliminate hepatitis C

The NHS will find and cure tens of thousands more people with hepatitis C as part of a ground-breaking deal that could help England become the first country in the…

Designer drugs to inhibit hepatitis A virus

Structure-based drug design revealed that a compound previously investigated for the treatment of head-and-neck cancer could function as a lead compound for the development of drugs to treat hepatitis A…

Arrowhead begins triple-combination HBV therapy trial

Arrowhead Pharmaceuticals began dosing in a new phase 1/2 study designed to evaluate a triple combination therapy that includes JNJ-3989 (formally ARO-HBV) and two undisclosed agents selected by Janssen Pharmaceuticals…

Antiviral therapy may prevent liver injury in hepatitis B/TB co-infection

Receiving antiviral treatment for hepatitis B (HBV) at the time of tuberculosis (TB) diagnosis reduced hospitalizations as a result of drug-induced liver injury by 56%, indicating that patients with TB…

Conflicting laws may keep contaminated needles in circulation, add to hep C cases

MORGANTOWN, W.Va.--Acute hepatitis C infections rose 98 percent between 2010 and 2015 nationwide, largely because more people were injecting drugs. Using a new needle for every injection can slow the…

ILC 2019: Hepatitis elimination by 2030 in doubt as countries fail to scale up diagnosis and treatment

Most countries will struggle to eliminate hepatitis C by 2030 due to lack of investment and political will, missing a internationally-agreed target set by the World Health Organization, the International…

Occult hepatitis B in hepatitis C-associated hepatocellular carcinoma

Occult hepatitis B virus (HBV) infection was detected in 50% of patients with chronic hepatitis C virus (HCV) infection who also have chronic HCV-related hepatocellular carcinoma (HCC), according to data…

How the hepatitis B virus establishes persistent infection

New research sheds light on how a hepatitis B viral protein stimulates the expansion of immune cells that impair antiviral responses, according to a study published April 18 in the…

Treatment switch for hep B patients with renal, bone risk

SAN DIEGO — Patients with hepatitis B at particular risk for bone and renal harm from tenofovir disoproxil fumarate (TDF; Viread, Gilead Sciences) might benefit from a switch to tenofovir alafenamide…

Previous HAV vaccination does not reliably protect some patients with HIV

Study findings suggest that previous vaccination against hepatitis A virus infection does not reliably protect some people with HIV. Researchers found that more than half of people with HIV who…

1 3 4 5 6 7 112